Hepatitis B and C: A Growing Concern in Ethiopia
The study sheds light on Hepatitis infections in Ethiopia over recent years.
Mulugeta Getachew, Amanuel Teferi, Edosa Kebede
― 5 min read
Table of Contents
Hepatitis is when your liver gets upset and inflamed. This can happen for many reasons, like Infections from viruses and bacteria, or even from drinking too much alcohol or taking certain drugs. The most famous troublemakers among viruses are Hepatitis A, B, C, D, and E. Out of these, Hepatitis B and C are the big boys causing most of the problems. They spread easily through things like blood transfusions, unprotected sex, or even from mom to baby during childbirth.
A Big Problem Worldwide
Hepatitis is a global issue and can lead to serious health problems. It can cause liver damage, which is fancy talk for liver scarring (cirrhosis), liver failure, and even liver cancer. Sadly, it kills over 1.4 million people each year. Hepatitis B and C are responsible for about 96% of these deaths. Currently, there are around 257 million people living with Hepatitis B and 10 million with Hepatitis C. Out of these, about 80 million have serious infections that need attention. When not treated, about 30% of people with chronic Hepatitis B and 20% of those with chronic Hepatitis C might end up with liver cirrhosis or cancer, which is quite scary since liver cancer is among the most common types of cancer and a major cause of cancer-related deaths.
Worldwide, Hepatitis B infections vary a lot. Some places have high rates (more than 8%), while others have lower rates. Hepatitis C also follows a similar trend, with places having varying levels of infection. Most people infected with these viruses are found in low- and middle-income countries.
For example, in Africa, Hepatitis B has a prevalence of 6.1%, leading to nearly 88,000 deaths each year. Interestingly, how common the virus is can also change based on things like gender and where you live.
Focus on Ethiopia
In Ethiopia, researchers have been looking at how Hepatitis B and C are spreading in different areas. The findings suggest that viral hepatitis continues to be a significant problem for public health. One study found that liver disease led to about 12% of hospital admissions and around 3% of hospital deaths were tied to Hepatitis B and C infections.
However, information on how the infections are changing over time is lacking. So, a study aimed to look into Hepatitis B and C trends among Patients at Ambo General Hospital from 2018 to 2021.
How the Study Was Done
This study looked at patient data from Ambo General Hospital collected over a period of about four years. The hospital serves a city with a population of about 64,684 people, and there are only two public Hospitals in the area. The researchers focused on patients suspected of having Hepatitis B or C who had been tested between January 2018 and December 2021.
Who Was Included
To be part of this study, patients had to be suspected of having Hepatitis B or C, and their test results had to be properly recorded. Sadly, if the information was incomplete, those records were tossed out.
Getting the Data
Three laboratory technicians gathered data from the hospital's records, looking at patients suspected of having Hepatitis B or C. They pulled together information like age, sex, and the results of the tests.
Analyzing the Numbers
Using a computer program, researchers ran the numbers to see if any of the factors, like age or sex, had an impact on Hepatitis infections. They even used another program to check the trends over the years.
Keeping it Ethical
All steps in the study were done according to the approved guidelines from local health authorities to ensure that everything was ethical and respectful of patients' rights.
Who Tested Positive?
A total of 5,675 patients were tested for Hepatitis, and of those, 637 (about 11.2%) were male while 5,038 (about 88.8%) were female. The most commonly tested age group was between 15 and 34 years old, making up 86.2% of the participants.
How Many Had the Virus?
The study found that 6.4% of people tested positive for Hepatitis B, which means 365 out of 5,674 had the virus. For Hepatitis C, the positivity rate was lower at 2.1%, with just 11 out of 524 testing positive. Among the males, 12.1% had Hepatitis B, while only 5.72% of females tested positive. The rates for Hepatitis C were 5.7% in males and just 1.0% in females.
Old folks between 45 and 54 years old had the highest rates of Hepatitis B, while those aged 35 to 44 had a higher prevalence of Hepatitis C. Interestingly, the years 2018 and 2020 saw the highest percentages of infections for both Hepatitis B and C.
What Affects Hepatitis B Rates?
Analyzing the data showed that being male was linked to a higher chance of having Hepatitis B. Age didn’t seem to make a difference in this analysis.
The Hepatitis C Situation
When looking at Hepatitis C, only males had a notable link. But being male wasn’t significantly tied to having the virus according to the numbers.
Looking at Trends
The prevalence of Hepatitis B and C varied year by year. In 2018, the rate for Hepatitis B was 7.1%, which dropped slightly in the following years. Hepatitis C, on the other hand, had a lower rate initially, peaking at 5.5% in 2020 before dropping again.
What It All Means
Overall, the study found that Hepatitis B is more common than Hepatitis C in the tested population. There were more males than females who tested positive for both viruses. The older age group showed higher rates for Hepatitis B, while younger individuals had higher rates for Hepatitis C.
The fluctuating rates over the years highlight the need for continuous monitoring and access to testing and diagnosis. The health authorities should pay attention to this issue to help control the spread of these viruses.
More screenings, prevention strategies, and public awareness about Hepatitis are crucial to address this health challenge. After all, keeping our livers healthy is no laughing matter!
Title: Trend Analysis of Hepatitis B and C Virus Infections among Patients at Ambo General Hospital, West Shoa, Ethiopia: Retrospective Study
Abstract: BackgroundHepatitis B and C viruses affect the liver and can cause wider range of disease outcomes. Chronic HBV and/or HCV infection leaves a person susceptible to major liver diseases such liver cirrhosis or hepatic cell cancer later in life. They bear the greater portion of the mortality and morbidity associated with hepatocellular carcinomas and liver cirrhosis. MethodsA retrospective laboratory record review was conducted at Ambo General Hospital from January 2018 to December 2021. The retrieved data included the date of examination, age, sex and laboratory results of the HBV and HCV. Data were summarized and presented in the form of tables, figures, and frequencies to present the results. The data were analyzed using SPSS and Microsoft Excel. ResultsOver the course of 4 years, a total of 5675 individuals were examined for hepatitis at Ambo general hospital. Of the total individuals examined, 365(6.4%) and 15(2.1%) were positive for HBV and HCV respectively. HBV and HCV mixed infections accounted for 0.6% of the cases. HBV was highest prevalent in males (12.1%) than females (5.72%), while among seropositive of HCV, 7(5.7%) were males and 4(1.0%) were females. HBV and HCV were more prevalent among individuals aged from 45-54 years old 11(11.6%) and 35-44 years old 4(5.6%) respectively. A high percentage of HBV (7.1%) and HCV (5.5%) were seen in the years of 2018 and 2020 respectively. ConclusionAccording to WHO criteria, the total prevalence of hepatitis B and C in our study is moderate, and the prevalence of HBV is significantly higher than that of HCV. Although, there are annual fluctuations in the prevalence. As a result, it is critical to improve coverage of services in healthcare facilities and raise community awareness regarding the means of transmission, prevention and control of hepatitis B and C virus infection.
Authors: Mulugeta Getachew, Amanuel Teferi, Edosa Kebede
Last Update: 2024-11-02 00:00:00
Language: English
Source URL: https://www.medrxiv.org/content/10.1101/2024.10.31.24316472
Source PDF: https://www.medrxiv.org/content/10.1101/2024.10.31.24316472.full.pdf
Licence: https://creativecommons.org/licenses/by/4.0/
Changes: This summary was created with assistance from AI and may have inaccuracies. For accurate information, please refer to the original source documents linked here.
Thank you to medrxiv for use of its open access interoperability.